author-photo

James Reeves

Sarah Cannon Research Institute

29

Papers

4209

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

2018 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (487)
A phase 2 study of the sphingosine‐1‐phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma

2017 Cancer
Show All
- Source
- Cite
- Save
Citations (24)
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (108)
Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

2015 Blood
Show All
- Source
- Cite
- Save
Citations (29)
STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
521PINTERIM SAFETY RESULTS FROM STEAM: A RANDOMIZED PHASE 2 TRIAL OF SEQUENTIAL AND CONCURRENT FOLFOXIRI–BEVACIZUMAB (BEV) VS FOLFOX–BEV FOR THE FIRST-LINE (1L) TREATMENT (TX) OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416)

2013 Blood
Show All
- Source
- Cite
- Save
Citations (13)
High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium

2013 Clinical Genitourinary Cancer
Show All
- Source
- Cite
- Save
Citations (6)
Rituximab +/− Bevacizumab for Patients with Previously Treated Follicular Non-Hodgkins Lymphoma: A Randomized Phase II Trial of the Sarah Cannon Research Institute.

2012 Blood
Show All
- Source
- Cite
- Save
Citations (0)